Anti-TT and anti-DT IgG titres in cohort 2 patients with CKD and controls with known vaccination history.

<p>Antigen-specific IgG titres (μg/ml) in cohort 2 CKD patients and age-matched controls (n = 22 and 19 respectively) are shown with medians for individuals vaccinated with TT/DT booster in preceding 10 years (blue) and those who were not (orange). The median for anti-DT IgG in controls not boosted within preceding 10 years is 0.01. A–anti-TT IgG; B–anti-DT IgG. Two-tailed Mann-Whitney p values are shown.</p

CMV-specific IgG titres in seropositive patients with CKD and controls.

<p>Serum CMV-specific IgG titres are shown only for seropositive patients with CKD and controls (ELISA titre greater than 10 arbitrary units, log₁₀ = 1) A: cohort 1 (n = 29 patients with CKD and 22 controls). B: cohort 2 (n = 21 patients with CKD and 13 controls). Error bars represent the median and interquartile range. Mann-Whitney 2-tailed p values shown.</p

Summary of demographic, clinical and laboratory data for cohort 2 patients with CKD and controls.

<p>Summary of demographic, clinical and laboratory data for cohort 2 patients with CKD and controls.</p

Serum-dependent killing of SEn in patients with CKD and controls.

<p>Killing curves of SEn strain D24954 by sera from A—a sub-group of cohort 1 with highest anti-LPS IgG titres: 10 patients with CKD and 9 controls; B–all patients with CKD and controls from cohort 2 (n = 25 and 20 respectively). Negative values correspond to a reduction in SEn compared with starting concentration. Antibody-depleted young healthy control serum (used as standard) served as a negative control. Error bars represent the mean +/- standard error of the mean.</p

Anti-TT and anti-DT IgG titres in cohort 1 patients with CKD and controls.

<p>Antigen-specific IgG titres (μg/ml) in cohort 1 CKD patients and age-matched controls (n = 43 and 39 respectively) are shown with medians and interquartile range. A–anti-TT IgG; B–anti-DT IgG. Two-tailed Mann-Whitney p values shown.</p

Summary of demographic, clinical and laboratory data for cohort 1 patients with CKD and controls.

<p>Summary of demographic, clinical and laboratory data for cohort 1 patients with CKD and controls.</p

Anti-LPS IgG titres in patients with CKD and controls.

<p>Serum anti-LPS IgG titres are represented relative to internal control serum from a single young healthy donor (arbitrary units, AU). A–cohort 1, B–cohort 2. Error bars represent the median and interquartile range. Mann-Whitney 2-tailed p values shown.</p